Vertex Pharmaceuticals reported that their investigational off-the-shelf stem cell therapy, zimislecel (previously VX-880), enabled 10 out of 12 type 1 diabetes patients to stop insulin therapy after one year. Presented at the American Diabetes Association meeting and published simultaneously in the New England Journal of Medicine, the therapy involves transplantation of lab-grown islet cells designed to restore endogenous insulin production. Patient outcomes included stable glycemic control without severe hypoglycemic events, marking a notable advance in regenerative approaches to diabetes treatment.